Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Equity Average (2016 - 2025)

Agios Pharmaceuticals' Equity Average history spans 13 years, with the latest figure at $1.2 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 21.79% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, down 21.79%, while the annual FY2025 figure was $1.4 billion, 16.25% up from the prior year.
  • Equity Average reached $1.2 billion in Q4 2025 per AGIO's latest filing, down from $1.3 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $2.0 billion in Q2 2021 to a low of $702.2 million in Q2 2024.
  • Average Equity Average over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
  • Peak YoY movement for Equity Average: skyrocketed 239.46% in 2021, then plummeted 41.98% in 2022.
  • A 5-year view of Equity Average shows it stood at $1.3 billion in 2021, then fell by 19.94% to $1.1 billion in 2022, then fell by 21.07% to $848.9 million in 2023, then skyrocketed by 86.57% to $1.6 billion in 2024, then dropped by 21.79% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Equity Average are $1.2 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.4 billion (Q2 2025).